Regus Susanne, Lang Werner, Heinz Marco, Uder Michael, Schmid Axel
1 Department of Vascular Surgery, University Hospital, Erlangen, Germany.
2 Institute of Radiology, University Hospital, Erlangen, Germany.
Vasc Endovascular Surg. 2017 Jul;51(5):233-239. doi: 10.1177/1538574417715182.
Local thrombolysis with a time of exposure to recombinant tissue plasminogen activator of 15 to 150 minutes is commonly used to declot acutely thrombosed hemodialysis fistulas. The duration of thrombolysis for the restoration of arteriovenous blood flow remains controversial. The aim of this study was to investigate the outcomes of long thrombolysis treatment (LTT, 3 hours or more) and short thrombolysis treatment (STT, less than 3 hours) in our institution.
We retrospectively analyzed 86 interventional declotting procedures (28 STT and 58 LTT) applied to 86 acutely thrombosed hemodialysis fistulas. The intervention time (IT) following thrombolysis (from the initial fistulography to the end of the angioplasty maneuvers), the time of day of the intervention (ie, during working hours vs off-hours), and the need for temporary catheter placement (TCP) were assessed. Success was defined as complete access recanalization, and major adverse events were defined as ischemia, bleeding, and access rupture.
The ITs were reduced after LTT (63.3 [9.3] minutes) compared to STT (106.7 [24.7], P = .01), but there was no difference in success rate (85.7% STT, 89.7% LTT, P = .722). While all (100%, 58/58) of the angioplasty maneuvers after LTT were performed during regular working hours, 75% (21/28) of those following STT were managed during off-hours ( P < .001). Despite the longer treatment, the need for TCP was not increased after LTT (10.7%) compared to STT (12.1%, P = .515), and the major complication rate was reduced (3.4% after LTT and 28.6% after STT, P = .004).
Long thrombolysis treatment results in shorter and less complicated percutaneous stenosis treatments during regular working hours. Despite the LTT of up to 25 hours until access for dialysis was achieved, no increase in the risks of TCP or major adverse events were observed following LTT.
局部溶栓治疗急性血栓形成的血液透析瘘管时,重组组织型纤溶酶原激活剂的暴露时间通常为15至150分钟。恢复动静脉血流的溶栓持续时间仍存在争议。本研究的目的是调查我院长时溶栓治疗(LTT,3小时或更长时间)和短时溶栓治疗(STT,少于3小时)的效果。
我们回顾性分析了应用于86例急性血栓形成的血液透析瘘管的86例介入性去凝程序(28例STT和58例LTT)。评估了溶栓后的干预时间(IT,从最初的瘘管造影到血管成形术操作结束)、干预的时间(即工作时间与非工作时间)以及临时导管置入(TCP)的需求。成功定义为通路完全再通,主要不良事件定义为缺血、出血和通路破裂。
与STT(106.7 [24.7]分钟)相比,LTT后IT缩短(63.3 [9.3]分钟,P = 0.01),但成功率无差异(STT为85.7%,LTT为89.7%,P = 0.722)。虽然LTT后的所有血管成形术操作(100%,58/58)均在正常工作时间内进行,但STT后的血管成形术操作有75%(21/28)在非工作时间进行(P < 0.001)。尽管治疗时间较长,但与STT(12.1%,P = 0.515)相比,LTT后TCP的需求并未增加(10.7%),且主要并发症发生率降低(LTT后为3.4%,STT后为28.6%,P = 0.004)。
长时溶栓治疗可使正常工作时间内经皮狭窄治疗时间缩短且并发症减少。尽管直到实现透析通路时LTT长达25小时,但LTT后未观察到TCP风险或主要不良事件增加。